Investigational drug · Phase 3
Ecnoglutide
Also called: XW003, VRB-101
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Weight Management, OSA - Obstructive Sleep Apnea.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
7 still active
All registered trials
17
Any phase or sponsor naming "Ecnoglutide"
First trial start
2025
Jul 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ecnoglutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Weight Management
- OSA - Obstructive Sleep Apnea
- Overweight , Obesity
- Knee Osteoarthritis
- Adolescents With Obesity
- Adolescents With Overweight & Weight-related Comorbidities
- Overweight and/or Obesity
- Overweight
Approved drugs for the same conditions: Obesity and weight management · Osteoarthritis · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Ecnoglutide" as an intervention, largest first.
- A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or ObesityPivotal-lookingCompleted
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT05813795 · 664 participants · Start Apr 5, 2023 · Primary completion Jun 20, 2024
Drug: Ecnoglutide Low Dosage; Ecnoglutide Medium Dosage and 2 more · For: Weight Management
Sites: Beijing, China
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMPivotal-lookingCompleted
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT05680129 · 623 participants · Start Jan 10, 2023 · Primary completion Jul 3, 2024
Drug: Ecnoglutide high dosage; Ecnoglutide low dosage and 2 more · For: T2DM; Type 2 Diabetes Mellitus
Sites: Shanghai, China
- A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)Pivotal-lookingRecruiting
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT07734311 · 360 participants (planned) · Start Aug 3, 2026 · Primary completion May 31, 2028
Drug: Ecnoglutide Injection; placebo with matching volume · For: Knee Osteoarthritis; Obesity
Sites: Wuhan, China
- A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or OverweightPivotal-lookingRecruiting
Verdiva Bio Dev LimitedIndustry
NCT07628127 · 332 participants (planned) · Start Jul 6, 2026 · Primary completion Mar 2028
Drug: VRB-103; VRB-101 · For: Obesity; Overweight
Sites: Brisbane, Australia; Melbourne, Australia · 3 sites in all
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM PatientsPivotal-lookingCompleted
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT05680155 · 211 participants · Start Dec 29, 2022 · Primary completion Jun 12, 2024
Drug: Ecnoglutide; Placebo · For: T2DM; Type 2 Diabetes Mellitus
Sites: Nanjing, China
- A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesPivotal-lookingCompleted
Verdiva Bio Dev LimitedIndustry
NCT07281937 · 206 participants · Start Nov 25, 2025 · Primary completion Jul 23, 2026
Drug: VRB-101; Placebo · For: Obesity; Overweight
Sites: Anniston, Alabama; Cullman, Alabama; Phoenix, Arizona · 22 sites in all
- A Study of Ecnoglutide Injection in Overweight or Obese Chinese AdolescentsPivotal-lookingNot yet recruiting
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT07836270 · 192 participants (planned) · Start Oct 31, 2026 · Primary completion Jun 8, 2028
Drug: Ecnoglutide Injection; placebo with matching volume · For: Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities
Sites: Hangzhou, China
- A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityPivotal-lookingNot yet recruiting
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT07929298 · 180 participants (planned) · Start Nov 10, 2026 · Primary completion Sep 3, 2027
Drug: ecnoglutide tablet; placebo with matching dosage · For: Overweight , Obesity; Weight Management
Sites: Luoyang, China
- A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)Pivotal-lookingActive, not recruiting
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT07073417 · 163 participants · Start Jul 28, 2025 · Primary completion Feb 27, 2027
Drug: XW003 injection; semaglutide injection · For: Obesity; Weight Management
Sites: Beijing, China
- A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure TherapyPivotal-lookingRecruiting
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT07434050 · 140 participants (planned) · Start Mar 2, 2026 · Primary completion Jun 19, 2028
Drug: XW003 injection; placebo with matching volume · For: OSA - Obstructive Sleep Apnea; Obesity
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Tong LH, Leung KK, Hung CT · J Chromatogr A 2026
- Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy.
Feng Y, Sun C, Li X, et al. · Front Endocrinol (Lausanne) 2026
- Ecnoglutide: First Approvals.
Shirley M · Drugs 2026
- Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants.
Li F, Du C, Yu Q, et al. · Diabetes Obes Metab 2026
- Evaluating the therapeutic benefits and safety of ecnoglutide for type 2 diabetes: evidence from a systematic review and meta-analysis.
Abunada S, Abunada O, Vivek F, et al. · Diabetol Metab Syndr 2026
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
Nong K, Shi Q, Xie X, et al. · BMJ 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.